Medical & affiliate disclosure: CTX Stat provides educational laboratory information and is not a substitute for professional medical advice, diagnosis, or treatment. CTX Stat may receive compensation from some outbound provider links when an affiliate program is active; provider comparisons and rankings are based on consumer fit, effective cost, access, policies, and reputation—not commission.
Quick take
- Whole exome sequencing is a broad genetic test that reads most protein-coding regions of genes, called exons. These regions represent a small portion of the genome but include many variants known to cause inherited disease.
- WES is most useful when the medical question is broad: developmental delay, congenital anomalies, neurologic symptoms, unexplained multisystem disease, or a suspected rare genetic disorder without a clear single-gene target.
- A result can be diagnostic, negative, uncertain, or unrelated to the reason for testing. A negative result does not rule out a genetic condition.
- Trio testing, which includes the affected person and both biological parents, can improve interpretation for many pediatric and rare-disease questions.
- Before ordering, clarify the exact test type, whether insurance authorization is needed, whether genetic counseling is included, what secondary findings may be returned, how family samples are handled, and what the total out-of-pocket cost may be.
On this page
What is whole exome sequencing?
Whole exome sequencing, often shortened to WES or exome sequencing, is a next-generation sequencing test that focuses on the exons: the parts of genes that contain instructions for making proteins. The U.S. National Library of Medicine explains that exome sequencing checks the parts of DNA that provide instructions to make proteins, while genome sequencing checks DNA more broadly across the genome. MedlinePlus Genetics also notes that broad sequencing can identify many more changes than targeted testing, but the meaning of some findings may be unknown.
The word “whole” can be misleading. WES does not perfectly read every exon in every gene, and it does not evaluate all DNA. Some exons may have low coverage, repetitive sequence, or technical limitations that make them hard to analyze. In addition, many clinically important changes occur outside coding regions. The National Human Genome Research Institute describes WES as a way to focus on the protein-coding regions rather than the entire genome, and it notes that exome testing is generally cheaper than whole genome sequencing because less DNA is sequenced. NHGRI’s comparison of exome and genome sequencing is a useful overview of this distinction.
In clinical care, WES is usually ordered to look for a genetic explanation for a person’s symptoms. It is different from recreational ancestry testing, wellness genotyping, or most consumer trait reports. A diagnostic WES report should connect genetic findings to the medical question, explain the evidence behind the interpretation, and identify whether follow-up testing or family testing is recommended.
Who may benefit from whole exome sequencing?
WES is not the first test for every health concern. It is most appropriate when a clinician suspects a genetic condition but the likely cause is not obvious. Examples include a child with developmental delay and congenital differences, a person with seizures plus other unexplained features, a family with multiple affected relatives but no known diagnosis, or a patient whose symptoms overlap many possible rare disorders.
The American College of Medical Genetics and Genomics strongly recommends that exome or genome sequencing be considered as a first- or second-tier test for pediatric patients with one or more congenital anomalies, developmental delay, or intellectual disability. That recommendation is specific to those clinical scenarios, not a blanket recommendation for population screening. You can line abstract at PubMed and the full guideline through Genetics in Medicine.
WES may also be considered after a targeted test is negative. For example, if a single-gene test, multigene panel, chromosomal microarray, or metabolic workup does not explain the symptoms, WES may broaden the search. However, the reverse can also be true: if the clinical picture strongly suggests a condition caused by a repeat expansion, methylation abnormality, large deletion, mitochondrial DNA variant, or chromosome-level change, another test may be a better first choice.
Situations where a narrower test may be better
A targeted panel may be preferable when the symptoms fit a well-defined category, such as hereditary breast and ovarian cancer, cardiomyopathy, hearing loss, or a known familial variant. Panels can provide deeper coverage of selected genes, may include deletion and duplication analysis tailored to those genes, and may be easier for insurers to authorize. Single-gene testing can be the cleanest option when a known familial variant needs confirmation.
WES is also not a general “find everything wrong” test. It does not predict most common adult diseases with high certainty, and it cannot replace a physical exam, imaging, biochemical testing, or other clinical evaluation. The best test depends on the reason for testing.
What whole exome sequencing can find—and what it can miss
Most clinical WES tests look for small DNA changes in coding regions, including single-nucleotide variants and small insertions or deletions. Some laboratories also analyze selected copy number variants, mitochondrial DNA, or a curated set of noncoding regions, but these features vary by lab and must be confirmed before ordering.
| Question | What to ask before ordering | Why it matters |
|---|---|---|
| Does the test include only the proband, or a trio? | Ask whether parents or other relatives are sequenced and analyzed at the same time. | Family samples can help determine whether a variant is inherited, new, or segregates with disease. |
| Are copy number changes included? | Ask whether exon-level deletions and duplications are analyzed and whether confirmation is included. | Some genetic diagnoses involve missing or duplicated DNA, not only spelling changes. |
| Are mitochondrial DNA findings included? | Ask whether mitochondrial genome sequencing is part of the test or requires a separate order. | Many exome tests focus on nuclear genes and may not fully evaluate mitochondrial disease. |
| Are secondary findings optional? | Ask what medically actionable gene list is used and whether you can opt in or out. | Secondary findings may reveal health risks unrelated to the symptoms that led to testing. |
| Is reanalysis available? | Ask whether the lab offers reinterpretation after 1–3 years or if new symptoms develop. | Gene-disease knowledge changes over time, so a nondiagnostic result may become informative later. |
Important limitations
WES may miss variants in regions that are not captured or not well covered, deep intronic variants, regulatory variants, repeat expansions, balanced chromosome rearrangements, methylation disorders, low-level mosaicism, and some structural variants. It may also miss a diagnosis if the gene has not yet been linked to disease or if the patient’s clinical information is incomplete.
Laboratory quality matters. The ACMG technical standard for constitutional next-generation sequencing describes expectations for clinical labs performing panel, exome, and genome testing, including validation, coverage, variant calling, and reporting considerations. The standard is available in Genetics in Medicine.
Singleton, duo, trio, and family exome testing
A singleton exome analyzes one person. A duo usually includes the affected person and one parent or another close relative. A trio includes the affected person and both biological parents. Some laboratories offer larger family exome testing when siblings or other relatives are important for interpretation.
Trio testing is especially useful when the affected person is a child and the question is whether a variant is de novo, meaning new in the child and not present in either parent. It can also help clarify recessive inheritance, X-linked inheritance, and whether a variant is more likely to explain the person’s symptoms. Trio testing does not guarantee a diagnosis, but it can reduce uncertainty and shorten follow-up because the inheritance pattern is available during the first analysis.
If one or both biological parents are unavailable, WES can still be useful. The ordering clinician may choose singleton testing, testing of another informative relative, or a staged approach where family testing is added later for specific variants.
How whole exome sequencing results are interpreted
WES generates a large amount of data. The laboratory does not usually list every genetic difference found. Instead, it filters and interprets variants based on the person’s symptoms, family history, inheritance pattern, population frequency, predicted effect on the protein, published evidence, disease databases, and professional variant-classification guidelines.
The widely used ACMG/AMP framework classifies sequence variants into categories such as pathogenic, likely pathogenic, uncertain significance, likely benign, and benign. The original consensus recommendations are available through PubMed and help explain why a laboratory may report a variant as disease-causing, uncertain, or not clinically meaningful.
| Result type | What it usually means | Practical next step |
|---|---|---|
| Positive / diagnostic | A pathogenic or likely pathogenic variant fits the symptoms and inheritance pattern. | Review the diagnosis, management implications, family testing, and reproductive risks with the clinician or genetic counselor. |
| Negative / nondiagnostic | No reportable variant was found under the lab’s methods and reporting rules. | Do not assume the condition is not genetic. Ask whether reanalysis, another test type, or a specialist evaluation is appropriate. |
| Variant of uncertain significance | A variant was found, but current evidence is not enough to call it disease-causing or benign. | Avoid major medical decisions based only on a VUS. Family studies, phenotype review, or future reclassification may help. |
| Secondary finding | A medically actionable variant unrelated to the original testing reason may be reported if the patient consented. | Confirm the result and discuss screening or prevention steps with the appropriate specialist. |
| Carrier finding | A person carries one variant for a recessive condition and usually is not affected by that condition. | Discuss reproductive implications, especially if a partner could carry a variant in the same gene. |
Secondary findings: decide before the test
Clinical exome and genome tests may look for certain medically actionable findings unrelated to the reason for testing, such as variants associated with hereditary cancer or inherited heart conditions. ACMG maintains a recommended secondary findings gene list for clinical exome and genome sequencing. The current published ACMG SF v3.3 list is available through PubMed Central.
Patients are typically asked whether they want these findings reported. This is an important consent decision. Some people want any medically actionable information that may help with prevention. Others prefer to focus only on the diagnostic question, especially when testing a child. Ask how the laboratory handles adult-onset conditions in minors, whether opt-out is allowed, and whether relatives may need follow-up if a secondary finding is identified.
Why a VUS should be handled carefully
A variant of uncertain significance is not a diagnosis. It means the lab found a change, but the evidence is incomplete or conflicting. Overinterpreting a VUS can lead to unnecessary anxiety, screening, procedures, or incorrect assumptions about family risk. If a VUS appears on a report, ask whether it fits the symptoms, whether parental or sibling testing could clarify it, and whether the lab has a process for reclassification updates.
What happens before and after ordering
For diagnostic medical use, WES is usually ordered by a genetics professional, specialist, or clinician familiar with the patient’s symptoms. Some primary care clinicians can order it, but broad sequencing is easier to interpret when the order includes detailed clinical information. Good phenotyping—accurate symptoms, age of onset, exam findings, imaging results, lab abnormalities, and family history—can directly affect what the lab prioritizes.
Before the sample is collected
- Clarify the clinical question. Write down the main symptoms, age of onset, prior test results, and what diagnosis or category is being considered.
- Ask whether genetic counseling is included. Pre-test counseling should cover possible result types, limitations, privacy, family implications, and secondary findings.
- Confirm the test scope. Ask whether the order is singleton, duo, trio, proband-only with parental samples for segregation, exome plus mitochondrial testing, or exome with copy number analysis.
- Review insurance requirements. Many insurers require prior authorization, medical-necessity documentation, or use of a specific laboratory network.
- Get cost details in writing when possible. Ask about the lab price, separate clinician or counseling fees, specimen collection charges, family-sample fees, data-release fees, and reanalysis fees.
- Ask about privacy and data access. Confirm whether raw data can be released, whether the data are stored, whether the sample is retained, and how deletion requests are handled.
Specimen collection
WES usually uses a blood sample, saliva sample, or cheek swab. Blood may be preferred in some situations because it can provide high-quality DNA and reduce sample-failure risk. Saliva and swab kits are convenient but may fail if there is not enough DNA, contamination, recent eating or drinking, or difficulty collecting a proper sample.
No fasting is usually required for germline WES. However, follow the collection kit instructions exactly. If a child, older adult, or medically complex patient may have trouble producing saliva, ask whether blood collection is recommended.
Turnaround time and follow-up
Turnaround time varies by lab, urgency, and whether family samples arrive together. Routine clinical WES often takes several weeks after the lab receives all required specimens and paperwork. Some labs offer expedited testing for urgent cases for an additional fee or under specific clinical criteria. For example, Blueprint Genetics’ public FAQ lists standard WES turnaround time in the 5–6 week range and describes an express option for some tests. Blueprint Genetics FAQ
When results return, schedule a visit to review them rather than relying only on the PDF. A report can contain inheritance details, limitations, and recommendations that are easy to misread without context. If the result is positive, the next step may include confirmatory testing, specialist referral, surveillance, medication changes, family testing, or reproductive counseling. If it is negative, the next step may be reanalysis, genome sequencing, RNA sequencing, methylation testing, repeat-expansion testing, chromosomal microarray, metabolic testing, or referral to an undiagnosed disease program.
Cost, insurance, and provider questions
The price of whole exome sequencing is not just the sticker price of the sequencing assay. The effective cost to the patient may include the genetics visit, counseling, prior authorization work, specimen collection, shipping, the proband test, parental or family samples, confirmatory testing, reanalysis, data release, and follow-up visits. If testing is billed through insurance, the final out-of-pocket cost depends on the plan’s coverage rules, deductible, coinsurance, network status, and medical-necessity determination.
Many clinical laboratories do not publish a simple cash price for WES because billing depends on insurance, institutional contracts, assistance programs, and the exact test configuration. When comparing options, ask each provider for the same set of facts so you are comparing total expected cost, not a partial price.
| Cost item | Ask this exact question | Who may charge it |
|---|---|---|
| Clinical visit | Is the genetics or specialist visit billed separately from the lab test? | Clinic, hospital, telehealth service |
| Pre-test counseling | Is counseling included, required, or billed separately? | Clinic, genetic counselor, ordering service |
| Lab test | What is the cash price and what is the estimated insurance out-of-pocket cost? | Clinical laboratory |
| Family samples | Are parental samples included in trio testing, or is each relative billed separately? | Clinical laboratory |
| Specimen collection | Is phlebotomy, kit shipping, or mobile collection included? | Lab, collection site, mobile service |
| Reanalysis | Is future reanalysis free, limited, or separately billed? | Clinical laboratory or clinic |
| Confirmatory testing | If a reportable variant is found, is confirmation included? | Clinical laboratory or separate lab |
| Follow-up care | Who reviews results and what visit fees apply? | Clinic, specialist, genetic counselor |
Clinical WES versus consumer sequencing
Some online companies sell whole genome sequencing or DNA data analysis directly to consumers at advertised prices that may be lower than clinical WES. Those products can be useful for data access or personal exploration, but they are not automatically equivalent to diagnostic clinical exome sequencing. A consumer report may not be accepted for medical decision-making without confirmation, may not include the same phenotype-driven interpretation, and may not provide the same family-based analysis.
If the goal is diagnosis, ask whether the test is ordered or reviewed by a licensed clinician, whether the laboratory is appropriately certified for clinical testing, whether the report is intended for medical use, whether variants are confirmed when needed, and whether a genetics professional will help interpret the findings. A lower checkout price is not necessarily a lower effective cost if you later need repeat testing through a clinical laboratory.
Privacy, family implications, and consent
WES can reveal information about biological relatives. A diagnosis in one person may show that parents, siblings, children, or future pregnancies have increased risk. It may also reveal nonpaternity, consanguinity, or unexpected biological relationships, depending on the family structure and analysis. These possibilities should be discussed before testing.
In the United States, the Genetic Information Nondiscrimination Act offers some protections against genetic discrimination in health insurance and employment, but it does not cover life insurance, disability insurance, or long-term care insurance. Because genetic data can have long-term implications, ask how the laboratory stores data, whether de-identified data may be used for research, whether you can opt out, and how to request data deletion or data release.
How to prepare for a genetics appointment
Bring a concise medical timeline, a three-generation family history if available, prior genetic test reports, imaging reports, specialist notes, and a list of current diagnoses. If the patient is a child, include prenatal history, birth history, developmental milestones, school supports, neurologic evaluations, growth records, and photographs only if the clinician requests them for dysmorphology assessment.
Ask the clinician to explain why WES is being chosen over a panel, microarray, genome sequencing, or another test. Also ask what result would change care. A useful pre-test conversation should make clear what WES can answer, what it cannot answer, and what the plan will be for positive, negative, and uncertain results.
When to consider reanalysis or another test
A nondiagnostic WES result may be worth revisiting. New disease genes are discovered, variant classifications change, and a person’s symptoms may evolve. Reanalysis can be especially useful if the original report is several years old, if new clinical features have appeared, or if a new family member has symptoms that change the inheritance pattern.
Another test may be more appropriate if the suspected condition involves repeat expansions, methylation changes, structural rearrangements, mitochondrial DNA, RNA splicing, low-level mosaicism, or noncoding variants. Whole genome sequencing may be considered when WES is negative and the suspicion for a genetic condition remains high, but genome sequencing also has limits and may still return uncertain or nondiagnostic results.
Bottom line
Whole exome sequencing is a powerful diagnostic tool when the medical question is broad and a genetic cause is plausible. Its value depends on choosing the right test, providing strong clinical information, understanding possible result types, and planning for follow-up. Before ordering, focus less on the word “whole” and more on the practical details: what is analyzed, who interprets it, what is not covered, what results you want returned, and what the total cost to the patient may be.
FAQs
Is whole exome sequencing a blood test?
It can be. Many clinical laboratories accept blood, saliva, or cheek-swab samples. Blood is often preferred when DNA quality is a concern, but the correct specimen depends on the lab and the patient’s situation.
Does WES test all genes?
WES is designed to analyze most protein-coding regions across many genes, but it does not perfectly cover every exon or every medically relevant region. Ask the laboratory for coverage details if a specific gene or condition is a major concern.
Can WES diagnose Ehlers-Danlos syndrome?
WES may identify variants associated with several rare Ehlers-Danlos syndrome types, but it does not confirm hypermobile EDS, which currently has no single known diagnostic gene. A genetics clinician can help decide whether a connective tissue panel, WES, or clinical evaluation is most appropriate.
Can WES detect cancer risk?
It may detect some inherited cancer-risk variants, especially if secondary findings are requested or if cancer predisposition is part of the testing indication. However, a dedicated hereditary cancer panel may be more appropriate when the main concern is personal or family cancer history.
Can WES be used before pregnancy?
WES is not the standard first-line test for routine carrier screening. People planning pregnancy are usually offered carrier screening panels based on guidelines, ancestry, family history, and reproductive goals. WES may be considered in specific situations, such as a previous affected child or fetal anomaly evaluation, under specialist guidance.
Will insurance cover whole exome sequencing?
Sometimes. Coverage is more likely when there is a documented medical need, a phenotype that fits payer criteria, and prior authorization. Coverage is less predictable for adult-onset nonspecific symptoms, screening, wellness use, or consumer-initiated testing.
Should I download my raw exome data?
Raw data can be useful for future reanalysis or specialist review, but it is easy to misinterpret. If you download FASTQ, BAM, CRAM, or VCF files, store them securely and avoid making medical decisions from third-party interpretations without clinical confirmation.
How often should WES be reanalyzed?
There is no universal interval. Many genetics clinics consider reanalysis after one to three years, or sooner if new symptoms, new family information, or new scientific evidence changes the clinical question.
Sources
- MedlinePlus Genetics: What are whole exome sequencing and whole genome sequencing?
- MedlinePlus Genetics: Types of genetic tests
- National Human Genome Research Institute: To sequence the exome or the genome?
- National Human Genome Research Institute: The cost of sequencing a human genome
- ACMG guideline: Exome and genome sequencing for pediatric patients with congenital anomalies or intellectual disability
- ACMG technical standard: Next-generation sequencing for constitutional variants
- ACMG/AMP standards and guidelines for sequence variant interpretation
- ACMG SF v3.3 secondary findings list
- Blueprint Genetics FAQ: WES turnaround time and express service
Educational note: This article is for general health education and does not diagnose, treat, or recommend a specific genetic test for any individual. Genetic testing decisions should be made with a qualified healthcare professional who can review the person’s symptoms, family history, prior testing, and goals.
